NextCure (NASDAQ:NXTC) had its price objective boosted by Bank of America from $27.00 to $44.00 in a research note released on Monday, BenzingaRatingsTable reports. The brokerage currently has a buy rating on the stock.

NXTC has been the subject of several other reports. Piper Jaffray Companies raised their target price on NextCure from $26.00 to $54.00 and gave the company an overweight rating in a research report on Thursday, September 5th. Morgan Stanley raised their target price on NextCure from $25.00 to $33.00 and gave the company an overweight rating in a research report on Tuesday, August 13th. Finally, Zacks Investment Research lowered NextCure from a hold rating to a sell rating in a research report on Thursday, September 5th.

NASDAQ NXTC opened at $37.68 on Monday. NextCure has a 12 month low of $13.86 and a 12 month high of $44.69. The company has a fifty day moving average of $27.84. The company has a quick ratio of 17.05, a current ratio of 17.05 and a debt-to-equity ratio of 0.02.

NextCure (NASDAQ:NXTC) last announced its earnings results on Monday, August 12th. The company reported ($0.61) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.46) by ($0.15). The firm had revenue of $1.40 million during the quarter, compared to analysts’ expectations of $1.50 million. Equities analysts expect that NextCure will post -1.89 EPS for the current year.

Hedge funds have recently bought and sold shares of the company. Victory Capital Management Inc. bought a new position in shares of NextCure during the 2nd quarter worth $48,000. Tower Research Capital LLC TRC bought a new position in shares of NextCure during the 2nd quarter worth $96,000. Morgan Stanley bought a new position in shares of NextCure during the 2nd quarter worth $101,000. Northern Trust Corp bought a new position in shares of NextCure during the 2nd quarter worth $337,000. Finally, Charles Schwab Investment Management Inc. bought a new position in shares of NextCure during the 2nd quarter worth $386,000. Institutional investors own 47.47% of the company’s stock.

NextCure Company Profile

There is no company description available for NextCure Inc

Featured Story: What are gap-down stocks?

Receive News & Ratings for NextCure Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NextCure and related companies with MarketBeat.com's FREE daily email newsletter.